Eisai Co Ownership
| ESALF Stock | USD 28.86 0.00 0.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Eisai |
Eisai Pink Sheet Ownership Analysis
About 50.0% of the company shares are held by institutions such as insurance companies. The book value of Eisai Co was currently reported as 2698.92. The company last dividend was issued on the 30th of March 2023. Eisai Co had 21:20 split on the 26th of March 1996. It offers Aricept for the treatment of alzheimers diseasedementia with Lewy bodies Methycobal for the treatment of peripheral neuropathy and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan. Eisai operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 11322 people.The quote for Eisai Co is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Eisai Co call Gary Hendler at 81 3 3817 3700 or check out https://www.eisai.co.jp.Currently Active Assets on Macroaxis
Other Information on Investing in Eisai Pink Sheet
Eisai Co financial ratios help investors to determine whether Eisai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eisai with respect to the benefits of owning Eisai Co security.